PMID- 34497187
OWN - NLM
STAT- MEDLINE
DCOM- 20210910
LR  - 20210910
IS  - 0485-1439 (Print)
IS  - 0485-1439 (Linking)
VI  - 62
IP  - 8
DP  - 2021
TI  - [What is the best treatment for chronic-phase CML?].
PG  - 1012-1023
LID - 10.11406/rinketsu.62.1012 [doi]
AB  - The chronic myeloid leukemia (CML) therapeutic landscape has dramatically changed 
      with the development of tyrosine kinase inhibitors (TKIs), which allows for a 
      near-normal life expectancy. Five TKIs have been currently approved for CML 
      treatment in Japan, of which four have been indicated as first-line therapy 
      (i.e., imatinib, nilotinib, dasatinib, and bosutinib). Nowadays, the long-term 
      prognosis of patients with CML is determined not by the primary disease but 
      rather by the comorbidities and treatment-related adverse events (AEs), including 
      cardiovascular events. Assessment of risk profile and comorbidities at diagnosis 
      is essential for the appropriate choice of TKI and long-term survival management. 
      The ability of some patients who achieve deep molecular responses to discontinue 
      therapy successfully is well documented. Long-term treatment-free remission with 
      continued response to TKI therapy is now recognized as the most optimal treatment 
      benefit for some patients.This article discusses treatment strategies, AE 
      management, and future perspectives based on the latest CML treatment guidelines.
FAU - Sakaida, Emiko
AU  - Sakaida E
AD  - Department of Hematology and Stem Cell Transplant Center, Chiba University 
      Hospital.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Rinsho Ketsueki
JT  - [Rinsho ketsueki] The Japanese journal of clinical hematology
JID - 2984782R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - RBZ1571X5H (Dasatinib)
SB  - IM
MH  - *Antineoplastic Agents/therapeutic use
MH  - Dasatinib/therapeutic use
MH  - Humans
MH  - Imatinib Mesylate/therapeutic use
MH  - *Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
MH  - Protein Kinase Inhibitors/therapeutic use
OTO - NOTNLM
OT  - Cardiovascular event (CVE)
OT  - Chronic myeloid leukemia (CML)
OT  - Treatment-free remission (TFR)
OT  - Tyrosine kinase inhibitor (TKI)
EDAT- 2021/09/10 06:00
MHDA- 2021/09/11 06:00
CRDT- 2021/09/09 06:09
PHST- 2021/09/09 06:09 [entrez]
PHST- 2021/09/10 06:00 [pubmed]
PHST- 2021/09/11 06:00 [medline]
AID - 10.11406/rinketsu.62.1012 [doi]
PST - ppublish
SO  - Rinsho Ketsueki. 2021;62(8):1012-1023. doi: 10.11406/rinketsu.62.1012.